# TC011

Source: https://onco.cc/drugs/tc011/  
OnCo record `tc011` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

TC011 is an experimental CAR-T cell therapy from TICAROS in phase 2 trials for diffuse large B-cell lymphoma and follicular lymphoma, aimed at CD19.

## Summary

TC011 is a CAR-T cell therapy developed by TICAROS. Its target is CD19 (the sponsor names CD19). The sponsor states: TC011 is an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, given after fludarabine/cyclophosphamide lymphodepleting chemotherapy, for relapsed/refractory large B-cell non-Hodgkin lymphoma. ClinicalTrials.gov describes the intervention as: Anti-CD19 Chimeric Antigen Receptor T cell. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in diffuse large B-cell lymphoma and follicular lymphoma. The largest, NCT07473167, plans to enrol 98 participants with primary completion expected 2028-02-11. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: CAR-T cell therapy
- Mechanism: TC011 is an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, given after fludarabine/cyclophosphamide lymphodepleting chemotherapy, for relapsed/refractory large B-cell non-Hodgkin lymphoma.

## Sources

- ClinicalTrials.gov: trials of TC011: https://clinicaltrials.gov/search?intr=TC011

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/)
- targets: [CD19](https://onco.cc/targets/cd19/)
- trials: [Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients](https://onco.cc/trials/nct07473167/)

---
JSON: https://onco.cc/api/v1/entities/tc011.json